Loxapine succinate
Suppliers
Names
[ CAS No. ]:
27833-64-3
[ Name ]:
Loxapine succinate
[Synonym ]:
2-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine succinate (1:1)
Succinic acid - 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine (1:1)
Daxolin
Butandisäure--2-chlor-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepin(1:1)
loxapine succinate salt
acide butanedioïque - 2-chloro-11-(4-méthylpipérazin-1-yl)dibenzo[b,f][1,4]oxazépine (1:1)
MFCD00069298
Loxitane
Cloxazepin
Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-, butanedioate (1:1)
Loxapac
EINECS 248-682-0
butanedioic acid,8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine butanedioate
Lederle
2-Chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine succinate
Loxapine succinate
Loxapine (succinate)
Chemical & Physical Properties
[ Boiling Point ]:
458.6ºC at 760mmHg
[ Melting Point ]:
150-152°C
[ Molecular Formula ]:
C22H24ClN3O5
[ Molecular Weight ]:
445.896
[ Flash Point ]:
231.1ºC
[ Exact Mass ]:
445.140442
[ PSA ]:
102.67000
[ LogP ]:
3.01860
[ Storage condition ]:
-20°C Freezer
[ Water Solubility ]:
H2O: soluble
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- WM5750000
- CAS REGISTRY NUMBER :
- 27833-64-3
- LAST UPDATED :
- 198910
- DATA ITEMS CITED :
- 3
- MOLECULAR FORMULA :
- C18-H18-Cl-N3-O.C4-H6-O4
- MOLECULAR WEIGHT :
- 445.94
- WISWESSER LINE NOTATION :
- T C676 BO INJ MG J- AT6N DNTJ D1 &QV2VQ
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 6 mg/kg/2D-I
- TOXIC EFFECTS :
- Behavioral - toxic psychosis
- REFERENCE :
- JCLPDE Journal of Clinical Psychiatry. (Physicians Postgraduate Press, Inc., POB 240008, Memphis, TN 38124) V.39- 1978- Volume(issue)/page/year: 44,37,1983
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 30 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold Behavioral - coma Lungs, Thorax, or Respiration - chronic pulmonary edema
- REFERENCE :
- CTOXAO Clinical Toxicology. (New York, NY) V.1-18, 1968-81. For publisher information, see JTCTDW. Volume(issue)/page/year: 14,181,1979
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 27 mg/kg/9D-I
- TOXIC EFFECTS :
- Endocrine - hyperglycemia
- REFERENCE :
- JCLPDE Journal of Clinical Psychiatry. (Physicians Postgraduate Press, Inc., POB 240008, Memphis, TN 38124) V.39- 1978- Volume(issue)/page/year: 44,347,1983
Safety Information
[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
[ Hazard Codes ]:
Xi
[ RIDADR ]:
UN 2811 6.1 / PGII
[ WGK Germany ]:
3
[ RTECS ]:
WM5750000
Articles
J. Pharm. Biomed. Anal. 58 , 83-93, (2012)
Loxapine represents an interesting example of old “new” drug and is recently drawing attention for its novel inhalation formulation for the treatment of both psychiatric and non-psychiatric disorders....
Int. J. Pharm. 403(1-2) , 101-8, (2011)
Medicinal aerosol products (metered dose and dry powder inhalers) require characterization testing over a wide range of use and pre-operating stress scenarios in order to ensure robust product perform...
Int. J. Clin. Pract. 66(3) , 318-25, (2012)
To describe the efficacy of inhaled loxapine for the treatment of agitation associated with schizophrenia or bipolar disorder using different examples of effect size (ES).Psychopharmacologic Drug Advi...